Cannon Global Investment Management LLC Takes $69,000 Position in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Cannon Global Investment Management LLC purchased a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) in the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 24,200 shares of the company’s stock, valued at approximately $69,000.

A number of other institutional investors have also recently made changes to their positions in the business. Howard Capital Management Inc. bought a new stake in Taysha Gene Therapies in the fourth quarter worth about $25,000. Victory Capital Management Inc. bought a new stake in Taysha Gene Therapies in the fourth quarter worth about $28,000. Dynamic Technology Lab Private Ltd bought a new stake in Taysha Gene Therapies in the fourth quarter worth about $31,000. China Universal Asset Management Co. Ltd. bought a new stake in Taysha Gene Therapies in the fourth quarter worth about $38,000. Finally, Chicago Partners Investment Group LLC lifted its stake in Taysha Gene Therapies by 21.4% in the fourth quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company’s stock worth $239,000 after purchasing an additional 23,740 shares during the last quarter. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Up 3.5 %

TSHA stock traded up $0.08 during trading on Friday, hitting $2.24. 28,053,032 shares of the company’s stock traded hands, compared to its average volume of 3,471,387. The firm has a market capitalization of $418.92 million, a P/E ratio of -4.57 and a beta of 0.50. The business has a fifty day simple moving average of $2.97 and a two-hundred day simple moving average of $2.41. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.75. Taysha Gene Therapies, Inc. has a 1 year low of $0.58 and a 1 year high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.01. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. The company had revenue of $3.41 million for the quarter, compared to analyst estimates of $3.70 million. During the same period last year, the company posted ($0.28) earnings per share. Sell-side analysts anticipate that Taysha Gene Therapies, Inc. will post -0.43 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on TSHA shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. BMO Capital Markets initiated coverage on shares of Taysha Gene Therapies in a research note on Thursday. They set an “outperform” rating and a $5.00 price target for the company. Piper Sandler initiated coverage on shares of Taysha Gene Therapies in a research note on Tuesday, April 9th. They set an “overweight” rating and a $9.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, June 18th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Taysha Gene Therapies presently has a consensus rating of “Buy” and a consensus target price of $6.80.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.